Conference Coverage

How common is accelerated knee OA?


 

REPORTING FROM OARSI 2019

– Accelerated knee osteoarthritis – a particularly noxious form of the joint disease – occurred in more than one in seven women who developed knee osteoarthritis in the prospective, long-term Chingford Cohort Study, Jeffrey B. Driban, PhD, reported at the OARSI 2019 World Congress.

OARSI mood shot Bruce Jancin/MDedge News

This finding from a unique prospective study of 1,003 middle-aged U.K. women who were followed for the development of knee osteoarthritis (OA) for 15 years is important because the participants represented a typical community-based population sample. And yet the Chingford results are consistent with and confirmatory of those found earlier in the Osteoarthritis Initiative, a U.S. cohort study of nearly 4,800 individuals, even though the Osteoarthritis Initiative featured a population enriched with established risk factors for knee OA, Dr. Driban explained at the meeting, sponsored by the Osteoarthritis Research Society International.

In Chingford, accelerated knee OA accounted for 15% of all incident cases of knee OA during follow-up, and for 17% of all newly affected knees, whereas 20% of incident knee OA in the Osteoarthritis Initiative was accelerated knee OA, noted Dr. Driban of Tufts University, Boston.

Accelerated knee OA is defined by rapidly progressive structural damage. Affected individuals streak from no radiographic evidence of knee OA to advanced-stage disease marked by a Kellgren-Lawrence score of 3 or more within 4 years, whereas the typical form of knee OA follows a more gradual course. Also, accelerated knee OA features greater pain and disability.

In the Chingford study, the cumulative incidence of accelerated knee OA was 3.9%, while typical knee OA occurred in 21.7% of women. During years 6-15 of follow-up, 21% of women with accelerated knee OA underwent total knee replacement, compared with 2% of those with typical knee OA and 0.9% of women without knee OA.

Dr. Driban reported having no financial conflicts regarding his analysis of the Chingford Cohort Study and the Osteoarthritis Initiative, supported by Arthritis Research UK and the National Institutes of Health, respectively.

SOURCE: Driban JB et al. Osteoarthritis Cartilage. 2019 Apr;27[suppl 1]:S250-S251, Abstract 352.

Recommended Reading

Warfarin boosts OA risk in Rotterdam Study
Clinician Reviews
Tanezumab acts fast for OA pain relief
Clinician Reviews
Scandinavian studies shed light on OA inheritance
Clinician Reviews
Methotrexate significantly reduced knee OA pain
Clinician Reviews
OA is underrepresented in the medical literature
Clinician Reviews
Swedish OA self-management program earns high marks
Clinician Reviews
Patient selection important for osteoarthritis structural and symptom endpoints
Clinician Reviews
Weight loss in knee OA patients sustained with liraglutide over 1 year
Clinician Reviews
Foot OA: Forgotten no longer
Clinician Reviews
Tanezumab improves osteoarthritis pain, function in phase 3 trial
Clinician Reviews